Clinical Trial Goal
To find out:
- The highest dose of REGN5837 that’s safe to give with odronextamab
- If the combination of REGN5837 and odronextamab is safe and works well to treat B-cell NHL that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have B-cell NHL that has relapsed or is refractory. Some examples include:
- Burkitt lymphoma
- Chronic lymphocytic leukemia/small-cell lymphocytic lymphoma (CLL/SLL)
- Diffuse large B-cell lymphoma (DLBCL)
- Follicular lymphoma
- Lymphoblastic lymphoma
- Marginal zone lymphoma (MZL)
- Primary Mediastinal large B-cell lymphoma (PMBCL)
- Waldenström macroglobulinemia
- Do not have lymphoma in your brain or spinal cord
- Do not have mantle cell lymphoma (MCL)
- Have not been treated with bispecific antibody drugs that target CD3 or CD20. Your doctor can tell you this
- Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Odronextamab is a bispecific antibody that targets CD3 and CD20 on certain cells.
REGN5837 is a bispecific antibody that targets CD22 and CD28 on certain cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
REGN5837 is a bispecific antibody that targets CD22 and CD28 on certain cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
- Odronextamab – Given as intravenous (IV) infusions
- REGN5837 - Given as IV infusions. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for as long as the clinical trial doctors think it’s best for your health. You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for about 5 years.
The Food and Drug Administration (FDA) has not yet approved odronextamab or REGN5837.
Locations
Sponsors
lead: Regeneron Pharmaceuticals
